echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Sansheng Pharmaceutical pre-charged Isep ® the production of new drugs for water needles received by the State Drug Administration

    Sansheng Pharmaceutical pre-charged Isep ® the production of new drugs for water needles received by the State Drug Administration

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Yesterday (July 29), China's leading bio
    pharmaceutical(http://company(http://Sansheng Pharmaceuticals (01530HK) announced that the antibody fusion proteindrug(http://product(http://®) developed by the company's Sansheng Guojian Pharmaceuticals (Shanghai) Co., Ltdhas submitted to the StateDrug(http://Regulatory Authority an application for the production of the new drug (http://   Pre-charged Essep ® hydroneedles (generic name: Recombinant Human Type II tumor necrosis receptor-antibody fusion protein injection) this pre-charged Isep ® water needle is China's first independently developed pre-filled fusion protein injection   Pre-filled Essep ® water needles are used in the treatment of three indications, namely active hypertrophic syllritis, moderate and severe active rheumatoid arthritis, moderate and severe plaque psoriasis in adults 18 years of age and over   According to the research, the prevalence of these three diseases in China is about 0.3% 1, 0.4%2, 0.1%3 respectively This pre-charged Isep ® water needles in the domestic biologics preparation process (http:// achieved a major breakthrough, so that patients are no longer limited to hospital treatment, but can inject themselves at home, is expected to greatly improve patients' drug compliance, improve the quality of life of patients   About Isep ®
    Isepop ®, which was launched in 2006 and has so far benefited more than 300,000 patients from treatment, has received professional recognition from clinicians and extensive patient trust, and was included in the National Health Insurance List class B drugs in 2017
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.